About us

SanaGen was incorporated in 2019 and is headquartered at the New West Health & Innovation District in Amsterdam, The Netherlands. SanaGen focuses on gene therapy approaches for rare genetic disorders and other debilitating diseases which can provide a durable, even life-long cure. SanaGen is a pioneering company that focuses not just on gene therapy, but also on exploring creative ways to reduce development costs, with an intent to introduce unique sales and contracting models for getting products to patients, and production built to serve both developed and developing countries. The goal is to develop gene therapy treatments not just for the developed world, but all the world’s patients. SanaGen develops these new gene therapies in collaboration with the research group of Prof. dr. Jan Voorberg of Sanquin Research and Prof. dr. Joost Verhaagen of The Netherlands Institute of Neuroscience. 

Our current portfolio includes the development of gene therapy for patients with factor VII and X deficiency. They are rare bleeding disorders which affect one in 300,000-500,000 people and current treatment for these disorders are suboptimal. Building on our extensive knowledge in the field of hemostasis as well as gene therapy development, we are also developing on gene therapy approaches for other bleeding disorders and liver-based genetic disorders. SanaGen aims to capitalize on over 3 decades of gene therapy research and experimentation, which has led to a rapidly innovating industry which is on the brink of treating many different genetic disorders.

SanaGen is founded and headed by David Mosmuller, MD PhD. He is a medical doctor with an entrepreneur mindset with extensive experience in clinical research, life sciences, medicine, regulatory affairs, and pharmacovigilance. The principal founders of SanaGen are experts in both basic and clinical studies on bleeding disorders and include experts with detailed knowledge on global markets for these disorders. 

David Mosmuller

MD, PhD, Co-Founder and CEO

David Mosmuller, MD, PhD, Co-Founder and CEO

David Mosmuller is a medical doctor with a business mindset who has extensive experience in team management, clinical research, life sciences, medicine, regulatory affairs, and pharmacovigilance. He has a PhD in medicine from the VU University Amsterdam and worked in the past within the medical affairs departments of Sanquin Plasma Products and Novo Nordisk in the Netherlands. With SanaGen he aims to disrupt the market by developing affordable gene therapy products for patients with rare bleeding disorders and making these therapies globally available.

Matthew Hotchko

PhD, MBA, Co-Founder and Board Member

Matthew Hotchko, PhD, MBA, Co-Founder and Board Member

Matthew Hotchko is a biotechnology industry veteran, who has helped a number of companies throughout his career, with a particular focus on how new technology can disrupt current marketplaces. He has spent most of his career in the plasma protein industry and is an expert in that space. Dr. Hotchko received his MS and PhD degrees in Biochemistry from the University of California, San Diego and his MBA from San Diego State University. He graduated with a Bachelor’s of Science degree in Chemistry from Gonzaga University.

Bas Blits

PhD, Principal Scientist

Bas Blits, PhD, Principal Scientist

Bas Blits is a passionate scientist with 20+ years of experience in the field of gene therapy. After obtaining his PhD on gene therapeutic strategies for spinal cord repair he went for his Postdoctoral training to the Miami Project to Cure Paralysis before joining AMT (currently UniQure), where he spent 10 years of his career. At UniQure he was head of the neurobiology research department with several research programs in the pipeline up till the preclinical stage. He later worked at DegenRx, developing a gene therapeutic strategy against amyloid beta oligomers for Alzheimer’s Disease and is currently also working part-time at Syngle Therapeutics for Parkinson’s disease. At SanaGen, Bas is responsible for the research and development of gene therapy for rare bleeding disorders.

SanaGen: one step closer to a cure for genetic disorders